Novo Nordisk must stay ready to increase Wegovy sales, says CFO

Serious production difficulties in the US mean that Novo Nordisk wil only receive limited amounts of obesity drug Wegovy over the next six months. However, the company promises that its salespeople are chomping at the bit to get going as soon as the problems are solved.

Group CFO Karsten Munk Knudsen | Photo: Novo Nordisk / PR

Novo Nordisk's latest issue with meeting patient demand for obesity drug Wegovy arose just one week after its sales force were called to a meeting in Las Vegas to prepare a large-scale sales campaign.

Now, however, the salespeople must prepare for six months where Novo's production is severely limited, and patients that are already in treatment will be prioritized. This means there will be very few new patients that start taking Wegovy in the first half of 2022.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs